April 21, 2014
The Japan Pharmaceutical Manufacturers Association’s (JPMA) Compliance Committee concluded on April 17 that Novartis Pharma deserves the membership suspension over its involvement in the SIGN clinical trial for its chronic myeloid leukemia drug Tasigna (nilotinib). The JPMA made its decision...read more